Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 5 | 2015 | 17 | 1.340 |
Why?
|
| Managed Care Programs | 6 | 2017 | 275 | 1.090 |
Why?
|
| Health Expenditures | 3 | 2014 | 69 | 0.830 |
Why?
|
| Diverticulitis, Colonic | 2 | 2014 | 8 | 0.810 |
Why?
|
| Middle Aged | 20 | 2021 | 7515 | 0.580 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 393 | 0.560 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2018 | 30 | 0.530 |
Why?
|
| Data Collection | 3 | 2014 | 223 | 0.520 |
Why?
|
| Febrile Neutropenia | 1 | 2017 | 3 | 0.510 |
Why?
|
| Algorithms | 2 | 2020 | 210 | 0.510 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2014 | 64 | 0.490 |
Why?
|
| Antirheumatic Agents | 3 | 2015 | 9 | 0.490 |
Why?
|
| Retrospective Studies | 12 | 2021 | 2463 | 0.490 |
Why?
|
| Aged | 17 | 2021 | 5901 | 0.470 |
Why?
|
| Male | 19 | 2021 | 9556 | 0.460 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 6 | 0.460 |
Why?
|
| Asthma | 2 | 2016 | 375 | 0.460 |
Why?
|
| Female | 19 | 2021 | 12193 | 0.450 |
Why?
|
| Humans | 22 | 2021 | 16832 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 203 | 0.440 |
Why?
|
| Diverticulitis | 1 | 2014 | 2 | 0.430 |
Why?
|
| Electronic Health Records | 3 | 2020 | 702 | 0.420 |
Why?
|
| Inpatients | 1 | 2014 | 78 | 0.410 |
Why?
|
| Outpatients | 1 | 2014 | 99 | 0.410 |
Why?
|
| Health Care Costs | 1 | 2015 | 192 | 0.410 |
Why?
|
| Consumer Behavior | 2 | 2004 | 27 | 0.400 |
Why?
|
| Ambulatory Care | 1 | 2014 | 205 | 0.380 |
Why?
|
| Mental Health | 1 | 2014 | 161 | 0.380 |
Why?
|
| Young Adult | 8 | 2015 | 2456 | 0.380 |
Why?
|
| Adolescent | 9 | 2015 | 3464 | 0.370 |
Why?
|
| Self Report | 1 | 2014 | 248 | 0.370 |
Why?
|
| Adult | 12 | 2016 | 7255 | 0.350 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 410 | 0.330 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 353 | 0.330 |
Why?
|
| Acute Coronary Syndrome | 2 | 2021 | 18 | 0.320 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 913 | 0.320 |
Why?
|
| California | 9 | 2019 | 2244 | 0.310 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1887 | 0.300 |
Why?
|
| Acute Disease | 3 | 2014 | 144 | 0.300 |
Why?
|
| Comorbidity | 4 | 2015 | 516 | 0.300 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2019 | 53 | 0.280 |
Why?
|
| Cohort Studies | 6 | 2020 | 2396 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 229 | 0.230 |
Why?
|
| United States | 6 | 2015 | 3858 | 0.230 |
Why?
|
| Drug Information Services | 1 | 2004 | 3 | 0.210 |
Why?
|
| Drug Industry | 1 | 2004 | 4 | 0.210 |
Why?
|
| Advertising as Topic | 1 | 2004 | 9 | 0.210 |
Why?
|
| Formularies as Topic | 1 | 2004 | 2 | 0.200 |
Why?
|
| Leukocytosis | 2 | 2014 | 5 | 0.200 |
Why?
|
| Abdominal Pain | 2 | 2014 | 13 | 0.200 |
Why?
|
| Treatment Outcome | 3 | 2018 | 1098 | 0.200 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2004 | 22 | 0.200 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 325 | 0.200 |
Why?
|
| Fever | 2 | 2014 | 52 | 0.200 |
Why?
|
| Odds Ratio | 4 | 2015 | 569 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2021 | 10 | 0.170 |
Why?
|
| Sex Factors | 3 | 2021 | 560 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 2 | 0.160 |
Why?
|
| Tonsillar Neoplasms | 1 | 2020 | 2 | 0.160 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 8 | 0.160 |
Why?
|
| Exercise Test | 1 | 2020 | 36 | 0.150 |
Why?
|
| Urinary Bladder | 1 | 2019 | 9 | 0.150 |
Why?
|
| Hospitalization | 2 | 2017 | 816 | 0.150 |
Why?
|
| BCG Vaccine | 1 | 2019 | 8 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 55 | 0.150 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 520 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 19 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 58 | 0.140 |
Why?
|
| Recurrence | 2 | 2016 | 149 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2021 | 1047 | 0.140 |
Why?
|
| Incidence | 3 | 2017 | 1229 | 0.140 |
Why?
|
| Logistic Models | 3 | 2015 | 796 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2019 | 145 | 0.130 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 15 | 0.130 |
Why?
|
| Disease Progression | 2 | 2016 | 252 | 0.130 |
Why?
|
| Mastectomy | 1 | 2018 | 34 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 60 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2019 | 249 | 0.130 |
Why?
|
| Blood Cells | 1 | 2016 | 3 | 0.120 |
Why?
|
| Eosinophils | 1 | 2016 | 10 | 0.120 |
Why?
|
| Age Factors | 2 | 2019 | 814 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2019 | 515 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2015 | 242 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 489 | 0.120 |
Why?
|
| Registries | 1 | 2018 | 449 | 0.110 |
Why?
|
| Medication Adherence | 2 | 2015 | 235 | 0.110 |
Why?
|
| Etanercept | 1 | 2015 | 3 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 84 | 0.110 |
Why?
|
| Adalimumab | 1 | 2015 | 3 | 0.110 |
Why?
|
| Hip Fractures | 1 | 2015 | 72 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2014 | 210 | 0.100 |
Why?
|
| Patient Preference | 1 | 2014 | 46 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 155 | 0.100 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2013 | 3 | 0.100 |
Why?
|
| Bupropion | 1 | 2013 | 9 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2013 | 11 | 0.100 |
Why?
|
| Nicotinic Agonists | 1 | 2013 | 15 | 0.100 |
Why?
|
| Sentinel Surveillance | 1 | 2013 | 12 | 0.100 |
Why?
|
| Benzazepines | 1 | 2013 | 24 | 0.100 |
Why?
|
| Continental Population Groups | 1 | 2014 | 255 | 0.100 |
Why?
|
| Prognosis | 1 | 2014 | 568 | 0.100 |
Why?
|
| Economics, Pharmaceutical | 1 | 2012 | 2 | 0.090 |
Why?
|
| Abscess | 1 | 2012 | 5 | 0.090 |
Why?
|
| Home Care Agencies | 1 | 2012 | 2 | 0.090 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 99 | 0.090 |
Why?
|
| Ethnic Groups | 1 | 2015 | 418 | 0.090 |
Why?
|
| Drug Costs | 1 | 2012 | 32 | 0.090 |
Why?
|
| Office Visits | 1 | 2012 | 78 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2013 | 140 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2012 | 164 | 0.080 |
Why?
|
| Risk Factors | 2 | 2014 | 3108 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 571 | 0.080 |
Why?
|
| United States Food and Drug Administration | 2 | 2013 | 33 | 0.080 |
Why?
|
| Time Factors | 1 | 2012 | 989 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 322 | 0.070 |
Why?
|
| European Continental Ancestry Group | 2 | 2019 | 400 | 0.050 |
Why?
|
| Hispanic Americans | 2 | 2019 | 350 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 12 | 0.050 |
Why?
|
| African Americans | 2 | 2019 | 394 | 0.050 |
Why?
|
| Texas | 1 | 2004 | 40 | 0.050 |
Why?
|
| Attitude | 1 | 2004 | 27 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 39 | 0.050 |
Why?
|
| Health Services Research | 1 | 2004 | 180 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1058 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 1233 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 19 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2019 | 2 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 69 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 291 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2020 | 60 | 0.040 |
Why?
|
| Cell Count | 1 | 2016 | 9 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 290 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 85 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 284 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 110 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 453 | 0.030 |
Why?
|
| Varenicline | 1 | 2013 | 12 | 0.020 |
Why?
|
| Health Behavior | 1 | 2015 | 332 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 1186 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2013 | 32 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 995 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 137 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 785 | 0.020 |
Why?
|
| Medicaid | 1 | 2013 | 189 | 0.020 |
Why?
|
Concepts
(144)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->